At a Glance

Aqualung Therapeutics Corporation is An early stage biotech company developing a therapeutic antibody to reduce inflammation in acute and chronic lung diseases. Aqualung Therapeutics Corporation has identified an upstream pathway and target which is a key contributor to the inflammatory storm associated with ventilator-induced lung injury as well as other chronic lung disorders such as pulmonary fibrosis, pulmonary arterial hypertension or radiation -induced lung injury.

The Problem

  • Unchecked inflammatory cascades are a root cause of the excessive morbidity and mortality in acute and chronic inflammatory lung disorders
  • The majority of ICU patients require mechanical ventilation (MV) for respiratory failure, however, MV directly causes lung inflammation and injury and contributes to ICU deaths, a syndrome known as Ventilator-Induced Lung Injury (VILI)
  • Approximately 40% of (ICU) patients are placed on mechanical ventilation within 24 hours of ICU admission

About Aqualung
Therapeutics

At A Glance

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eleifend eros eu enim tempor efficitur. Maecenas a enim sapien. Sed fringilla efficitur sem, id interdum risus vestibulum vitae.

Management

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eleifend eros eu enim tempor efficitur. Maecenas a enim sapien. Sed fringilla efficitur sem, id interdum risus vestibulum vitae.

Clinical Advisory Board

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque eleifend eros eu enim tempor efficitur. Maecenas a enim sapien. Sed fringilla efficitur sem, id interdum risus vestibulum vitae.

CONTACT US

The Team

JOE “SKIP” G.N. GARCIA

Md Founder And Chief
Executive Officer

EDDIE T. CHIANG

Ma,
Chief Operating Officer

SARA M. CAMP

Ba,
Chief Research Officer

STAN MIELE

Ba, Chief Business
trategy Officer

THE PROBLEM

Increased lung inflammation is a key contributor to increased mortality in acute and chronic lung disease. There are NO current therapies that effectively prevent or reduce lung inflammatory burden.

View All Projects